Board Appointment

RNS Number : 5255C

Scancell Holdings Plc

18 June 2019

 

18 June 2019

Scancell Holdings plc

("Scancell" or the "Company")

Board Appointment

Scancell, the developer of novel immunotherapies for the treatment of cancer, announces that, further to the Company's announcement on 13 June 2019, Martin Diggle, Co-Founder and Portfolio Manager of Vulpes Investment Management, has been appointed to the Company's Board of Directors (the "Board") as a Non-Executive Director with immediate effect.

Mr Diggle has over 30 years' experience in investment banking and fund management and has been an investor in life sciences and biotechnology companies for nearly 20 years. He is also an expert in Emerging Markets and Russia, where he was previously a partner and director of UBS Brunswick. He holds a Master's Degree in Philosophy, Politics and Economics from University of Oxford.

Additional Information

In accordance with the AIM Rules, the following information required to be disclosed in relation to Martin Diggle  is set out below. Other than this information, there is no further information required to be disclosed under paragraph (g) of Schedule Two of the AIM Rules.

Full name and age

Martin Henry Diggle, 57 years old

Current beneficial shareholding in the Company

Martin Diggle is a director and partner in Vulpes Investment Management and manages the Vulpes Life Sciences Fund which is the registered holder of 77,559,311 ordinary shares, representing approximately 16.67 per cent. of Scancell's ordinary share capital. 

Current Directorships	Past Directorships in the previous five years
Chronos Therapeutics Limited	N/A
Oxford BioMedica plc
Proteome Sciences plc

For Further Information:

Scancell Holdings plc
Dr John Chiplin, Chairman		[phone]
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited (Nominated Adviser and Corporate broker)
Freddy Crossley/Emma Earl		[phone]
FTI Consulting Simon Conway/Natalie Garland-Collins		[phone]

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody^® and Moditope^® technology platforms.

ImmunoBody^® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

·      SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

·      SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.

Moditope^® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope^® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

·      Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.

For further details, please see our website:  www.scancell.co.uk

 

END

 

 

BOAUBVVRKVANAAR